They are detected in 90–95% of patients, whereas specific ANAs, namely, Sp100 and gp-210, are only present in 50–70% of patients with PBC and in 30–50% of AMA-M2-negative PBC patients [1,2,4,5,7]. This evidence concerns the gene SP100 and primary biliary cholangitis.